Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes

Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes

IntroductionThe mRNA-based BNT162b2 (Pfizer-BioNTech) vaccine has been shown to elicit robust systemic immune response and confer substantial protection against the severe coronavirus disease (COVID-19), with a favorable safety profile in adolescents. However, no data exist regarding immunogenicity,...

Full description

Bibliographic Details
Main Authors: Hamdi Cihan Emeksiz, Merve Nur Hepokur, Sibel Ergin Şahin, Banu Nursoy Şirvan, Burçin Çiçek, Aşan Önder, Metin Yıldız, Derya Karaman Aksakal, Aysun Bideci, Hüsnü Fahri Ovalı, Ferruh İşman
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Pediatrics
Subjects:
BNT162b2 vaccine
COVID-19
immunogenicity
type 1 diabetes
adolescents
SARS-CoV-2
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1191706/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1191706/full

Similar Items